CN115925847A - MmPI在制备胰蛋白酶抑制剂中的应用 - Google Patents
MmPI在制备胰蛋白酶抑制剂中的应用 Download PDFInfo
- Publication number
- CN115925847A CN115925847A CN202211127625.5A CN202211127625A CN115925847A CN 115925847 A CN115925847 A CN 115925847A CN 202211127625 A CN202211127625 A CN 202211127625A CN 115925847 A CN115925847 A CN 115925847A
- Authority
- CN
- China
- Prior art keywords
- mmpi
- activity
- trypsin inhibitor
- trypsin
- mulberry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002753 trypsin inhibitor Substances 0.000 title claims abstract description 20
- 229940122618 Trypsin inhibitor Drugs 0.000 title claims abstract description 12
- 101710162629 Trypsin inhibitor Proteins 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 230000000694 effects Effects 0.000 claims abstract description 48
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 230000014509 gene expression Effects 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 239000013612 plasmid Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 240000000249 Morus alba Species 0.000 abstract description 23
- 235000008708 Morus alba Nutrition 0.000 abstract description 22
- 108090000631 Trypsin Proteins 0.000 abstract description 11
- 102000004142 Trypsin Human genes 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 239000012588 trypsin Substances 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 7
- 238000011161 development Methods 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 3
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 230000000007 visual effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 12
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000003001 serine protease inhibitor Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 8
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 229930027917 kanamycin Natural products 0.000 description 7
- 229960000318 kanamycin Drugs 0.000 description 7
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 7
- 229930182823 kanamycin A Natural products 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 108050000761 Serpin Proteins 0.000 description 4
- 102000008847 Serpin Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000009465 prokaryotic expression Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241000255789 Bombyx mori Species 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 235000006721 Morus bombycis Nutrition 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000433 anti-nutritional effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 239000003602 elastase inhibitor Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 235000013613 poultry product Nutrition 0.000 description 2
- 238000012257 pre-denaturation Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 229940122644 Chymotrypsin inhibitor Drugs 0.000 description 1
- 101710137926 Chymotrypsin inhibitor Proteins 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 244000293610 Morus bombycis Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 241000904454 Thespis Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 235000019730 animal feed additive Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Botany (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Fodder In General (AREA)
Abstract
本发明属于基因工程和酶工程技术领域,具体涉及MmPI在制备胰蛋白酶抑制剂中的应用。所述MmPI具有SEQ ID NO.1所示的氨基酸序列。本发明首次明确了桑叶中的MmPI具有胰蛋白酶抑制活性,并揭示了其理化特性,所述MmPI在制备胰蛋白酶抑制剂方面具有良好的应用前景,在明确其理化性质的基础上,可以针对性消除其活性,推动桑叶资源在动物饲粮中的开发利用,为桑叶在动物饲料、保健食品方面的开发利用提供新的视角和思路,提升桑资源的经济效益。
Description
技术领域
本发明属于基因工程和酶工程技术领域,具体涉及MmPI在制备胰蛋白酶抑制剂中的应用。
背景技术
桑叶作为一种优质、新型的动物饲料添加剂,不仅能提高动物生长性能、提升禽畜产品品质,也可避免桑叶资源浪费,提高蚕桑产业的综合经济效益。然而,由于桑叶中存在抗营养因子如单宁、蛋白酶抑制剂和植物凝集素,动物大量添食桑叶会严重干扰其对饲料营养的代谢和吸收,进而影响畜禽健康和畜禽产品的产量与质量,这也极大限制了桑叶资源在动物饲粮中的开发和应用。丝氨酸蛋白酶抑制剂(serine protease inhibitor,SPI)是蛋白酶抑制剂中数目最多,研究最为深入的一类,包括胰蛋白酶抑制剂(trypsininhibitor,TI)、胰凝乳蛋白酶抑制剂(chymotrypsin inhibitor,CI)、弹性蛋白酶抑制剂(elastase inhibitor,EI)和枯草杆菌蛋白酶抑制剂(subtilisin inhibitor,SI)等。
依据SPI的活性位点、作用机制及在植物中的分布状况,植物SPI可分为8个家族,其中研究较为深入的有Kunitz、Serpin、Bowman-Birk、PI-I和PI-II家族。川桑基因组中共鉴定出79个蛋白酶抑制剂(protease inhibitor,PI),其中SPI有35个,分别为Kunitz、Serpin和PI-I家族。分析不同SPI家族基因在各组织中的表达,发现8个Kunitz和1个Serpin家族SPI基因主要在桑叶中表达。Western Blot检测发现丝氨酸蛋白酶抑制剂MmKPI-9在桑叶中有表达,而胶内活性染色未检测到TI活性条带。王丹丹利用胶内活性染色技术从桑叶叶柄部流出的白色乳汁中检测到多个CI活性条带,而在桑树叶片中未检测到CI活性。目前,桑叶中抗营养因子类SPI的研究报道较少,且这些SPI的序列信息、活性、理化特性尚不清楚。
发明内容
为了解决上述技术问题,本发明提供了MmPI在制备胰蛋白酶抑制剂中的应用,所述MmPI具有SEQ ID NO.1所示的氨基酸序列。
基于同一个发明构思,本发明还提供了编码所述MmPI的基因,核苷酸序列如SEQID NO.2所示。
基于同一个发明构思,本发明还提供了携带所述基因的质粒。
基于同一个发明构思,本发明还提供了携带所述质粒的宿主表达菌株。
基于同一个发明构思,本发明还提供了所述菌株的表达产物在制备胰蛋白酶抑制剂中的应用。
基于同一个发明构思,本发明还提供了所述MmPI或所述菌株的表达产物的胰蛋白酶抑制活性消除方法,包括:将MmPI置于121℃,0.21MPa环境中处理20min;或,利用由还原糖介导的美拉德反应消除。
本发明具有如下有益效果:
本发明首次明确了桑叶中的MmPI具有胰蛋白酶抑制活性,并揭示了其理化特性,所述MmPI在制备胰蛋白酶抑制剂方面具有良好的应用前景,在明确其理化性质的基础上,可以针对性消除其活性,推动桑叶资源在动物饲粮中的开发利用,为桑叶在动物饲料、保健食品方面的开发利用提供新的视角和思路,提升桑资源的经济效益。
附图说明
图1为MmPI(Ma)的PCR产物电泳检测(A),以及MmPI(Ma)的菌液PCR产物电泳检测(B)。
图2为MmPI的核苷酸序列及其衍生的氨基酸序列。灰色背景部分为信号肽序列,下划线部分为PI结构域。起始密码子(ATG)和终止密码子(TAA)用方框标出。
图3为BL21(DE3)细胞中表达的MmSPI6和MmPI的SDS-PAGE分析(A),以及Origami 2(DE3)细胞中表达的MmSPI6和MmPI的SDS-PAGE分析(B)。“S”表示可溶性蛋白。“U”表示不可溶蛋白。“Control”,转入p28空载体的BL21(DE3)和Origami 2(DE3)菌株的细胞裂解物,MmSPI6为另一种丝氨酸蛋白酶抑制剂。
图4为BL21(DE3)细胞中表达的MmPI的TI(A)和CI(B)活性分析。“TI”和“CI”分别代表胰蛋白酶抑制剂和胰凝乳蛋白酶抑制剂。家蚕5龄第5天血液作为阳性对照。“Control”,转入p28空载体的BL21(DE3)菌株的细胞裂解物。箭头表示蛋白酶抑制剂活性条带。
图5为Origami 2(DE3)细胞中表达的MmPI的TI(A)和CI(B)活性分析。“TI”和“CI”分别代表胰蛋白酶抑制剂和胰凝乳蛋白酶抑制剂。家蚕5龄第5天血液作为阳性对照。“Control”,转入p28空载体的Origami 2(DE3)菌株的细胞裂解物。箭头表示蛋白酶抑制剂活性条带。
图6为不同pH对MmPI活性的影响。
图7为高温高压联用对MmPI活性的影响。
图8为β-巯基乙醇对MmPI活性的影响。
图9为美拉德反应对MmPI活性的影响。
具体实施方式
下面结合附图和具体实施例对本发明进行详细说明,但不应理解为本发明的限制。如未特殊说明,下述实施例中所用的技术手段为本领域技术人员所熟知的常规手段,下述实施例中所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
以下实施例涉及p28表达载体由陕西理工大学维生素D生理与应用研究所保存。
实施例1
1实验方法
1.1“金十”叶片中RNA提取和cDNA第一链的合成
1.1.1桑叶RNA的提取
采用Eastep Super总RNA提取试剂盒(Promega公司),按照说明书操作。
1.1.2cDNA第一链的合成
总RNA变性解链,取总RNA 4μg,加Oligo(dT)1μL,用RNase-free water补足至10μL。置于PCR仪42℃30min,再85℃5s,反应结束后迅速取出置于冰中,2.5倍稀释于-20℃保存。
RT-PCR反应体系:
1.2表达载体构建
1.2.1桑叶中抑制剂目的片段PCR扩增
基于白桑中蛋白酶抑制剂的CDS序列,对MmPI基因(名称为申请人团队自己设计、命名)设计引物。其引物序列见表1。
表1蛋白酶抑制剂MmPI克隆所用引物
注:下划线表示酶切位点。Nde I位点:CATATG;Not I位点:GCGGCCGC。下标为“Ma”表示基于白桑数据库所设计的引物。
以金十叶片cDNA为模板进行PCR扩增,PCR体系如下:
PCR扩增程序:95℃预变性2min;95℃变性30s,55℃退火30s,72℃延伸30s,35个循环;72℃再延伸10min。PCR产物经过1.5%琼脂糖凝胶电泳分离,并参照EasyPure PCRPurification Kit进行纯化,对PCR产物和p28载体进行双酶切,双酶切反应体系见表2。
表2双酶切反应体系
37℃过夜酶切后,加入10×Loading buffer终止酶切。酶切产物经1.5%琼脂糖凝胶电泳分离,参照EasyPure Quick Gel Extraction Kit切胶回收。
1.2.2目的片段与p28载体连接
将目的片段16℃2h连接到p28载体上,连接体系如下:
1.2.3转化
将连接产物转化入大肠杆菌DH5ɑ感受态细胞,具体转化步骤如下:
1)将DH5ɑ感受态细胞置于冰上,待其刚融化时,加入连接产物轻轻吹吸混匀,并置于冰上静置30min。
2)42℃热激90s,迅速置于冰上静置5min。
3)加入900μL不含抗生素的2-YT液体培养基,37℃220rpm培养1h。
4)3500rpm离心5min,弃上清800μL,移液枪重悬沉淀和上清,将重悬液加入含卡那霉素抗性的2-YT固体培养基,用灭菌后的涂布棒轻轻涂布于均匀。
5)37℃恒温培养箱中先正置10min,再倒置培养12h。
1.2.4菌液PCR筛选阳性克隆及测序
挑取6个大而圆润的白色单菌落,接种于600μL的含卡那霉素抗性的2-YT液体培养基中,37℃220rpm震荡培养4h。吸取2μL菌液为模板进行菌液PCR。菌液PCR反应体系如下:
PCR程序为:95℃预变性5min;95℃变性30s,55℃退火30s,72℃延伸1min或1min15s,30个循环;72℃再延伸10min。PCR产物经1.5%琼脂糖凝胶检测,能扩增出目的条带的菌液为阳性克隆。选择三个条带明亮的阳性克隆菌液各吸取200μL送至上海生工进行测序。
1.2.5制备甘油菌及质粒提取
按照1/100~1/1000比例吸取测序正确的菌液于含卡那霉素抗性的2-YT液体培养基,37℃220rpm,震荡培养12h;取300μL菌液中与200μL 50%的甘油混匀制备成甘油菌,-20℃保存。吸取2mL菌液,参考EasyPure Plasmid MiniPrep Kit提取质粒。
1.3MmPI的原核表达
1.3.1转化入大肠杆菌表达菌株
将质粒转入大肠杆菌BL21(DE3)和Origami 2(DE3)菌株,转化步骤如下:
1)-80℃保存的BL21(DE3)或Origami 2(DE3)感受态细胞置于冰上,待其刚刚融化时,取1μL的质粒轻轻地缓慢加入感受态细胞中轻柔混匀,冰浴30min。
2)42℃热激90s,热激结束快速插入冰中冷却5min。
3)加入不含抗生素的2-YT液体培养基900μL,37℃220rpm孵育1h。
4)3500rpm,离心5min,弃上清液800μL。
5)移液器混匀剩余上清液和沉淀,悬浊液分别置于含有一种抗生素(卡那霉素抗性)或三种抗生素(卡那霉素、链霉素、四环素)的2-YT固体培养基上,用灭菌过的涂布棒轻轻涂布均匀。
6)将固体平板在37℃培养箱中先正置10min,再倒置培养12h。
1.3.2诱导表达
1)挑取大而圆润的单菌落,分别置于600μL含有一种抗生素(卡那霉素抗性)或三种抗生素(卡那霉素、链霉素、四环素)的2-YT液体培养基,恒温摇床37℃220rpm过夜培养。
2)取过夜摇混的菌液150μL于15mL具有相应抗生素的2-YT液体培养基,37℃220rpm培养至菌液OD600=0.6~1.0时迅速插入冰中延缓生长。
3)按1/500比例加入0.1M IPTG贮藏液(即工作浓度0.2mM),37℃220rpm诱导5h或16℃220rpm诱导20h。
4)诱导结束后,4℃6000rpm离心20min,弃上清液。
5)加入1.5mL的1×结合缓冲液重悬菌体,4℃6000rpm离心10min,弃上清液。
6)再加入1mL的1×结合缓冲液重悬菌体,再次离心,弃上清液。
7)最后加入450μL 1×结合缓冲液重悬菌体,-20℃保存。
1.3.3细胞破碎
将菌体混匀物置于冰水混合物中,使用超声波破碎仪30W破碎至菌体混匀液透亮,4℃16000g,离心30min,分离上清,沉淀中加入250μL 1×结合缓冲液重悬,获得包涵体溶液,-20℃保存上清液及沉淀物。
1.4SDS-PAGE以及Native PAGE和MmPI的活性染色
操作步骤参照申请号为202111086415.1的中国专利。
1.5不同pH、高温高压联用、还原剂和美拉德反应对MmPI活性影响
操作步骤参照申请号为202111086415.1的中国专利。
2结果与分析
2.1MmPI的表达载体构建
经PCR扩增MmPI(Ma)得到明亮且单一的条带(图1A)。将PCR产物连接到p28载体上转入DH5ɑ感受态细胞,进行菌液PCR,并采用1%的琼脂糖凝胶电泳检测,结果如图1B所示。挑选阳性克隆的菌液,经过测序证实,MmPI(Ma)克隆成功。MmPI(Ma),命名为:MmPI。接下来,我们将提取基因质粒,并对其进行原核表达。
2.2MmPI的一级结构分析
MmPI的CDS编码框由288个核苷酸组成,序列如SEQ ID NO.2所示,编码一个有95个氨基酸的蛋白质,序列如SEQ ID NO.1所示。该蛋白无信号肽(图2)。MmPI蛋白成熟体分子量为10636.04Da,等电点(pI)为5.84,具有一个PI结构域。
2.3MmPI的原核表达
为了实现目的基因的原核表达,将质粒转入大肠杆菌BL21(DE3)和Origami2(DE3)两种表达菌株中,使用工作浓度为0.2mM的IPTG进行诱导表达。用16.5%的SDS-PAGE对目的蛋白进行分离检测,结果显示,MmPI在BL21(DE3)和Origami 2(DE3)菌株的上清中皆有表达(图3)。
2.4MmPI的活性分析
为了分析MmPI蛋白对胰蛋白酶和胰凝乳蛋白酶的抑制活性,我们利用10%的Native PAGE对BL21(DE3)和Origami 2(DE3)菌株中诱导表达MmPI蛋白进行分离后,进行胶内活性染色。结果表明,BL21(DE3)(图4)和Origami 2(DE3)(图5)菌株中诱导表达的MmPI皆能强烈抑制胰蛋白酶活性,但不抑制胰凝乳蛋白酶活性。相较于Origami 2(DE3)菌株,BL21(DE3)中的MmPI蛋白的活性更强。
2.5pH、温度、还原剂和美拉德反应对MmPI活性的影响
(1)不同pH对MmPI活性的影响
如图6所示,蛋白酶抑制剂MmPI具有很强的酸碱稳定性,在pH 3~11范围内,其对胰蛋白酶的抑制活性基本保持稳定。
(2)高温高压联用对MmPI活性的影响
为验证高温或高温高压联用对蛋白酶抑制剂MmPI活性的影响,我们将蛋白酶抑制剂置于121℃0.21MPa或100℃处理20min,之后经Native PAGE和胶内活性染色分析其对胰蛋白酶的抑制活性。胶内活性染色结果显示(图7),相比于对照组,100℃处理会使MmPI对胰蛋白酶的抑制活性略有降低,而高温高压联用(121℃0.21MPa)可使MmPI的胰蛋白酶抑制活性完全丧失。需要注意的是,热处理20min后MmPI活性条带的位置向下迁移,提示加热引起了MmPI构象发生改变。总之,高温高压联用基本能够消除MmPI对胰蛋白酶的抑制剂活性。
(3)还原剂对MmPI活性的影响
为了探究还原剂对MmPI活性的影响,我们采用β-巯基乙醇对蛋白酶抑制剂MmPI进行处理,并分析其对胰蛋白酶的抑制活性。结果如图8所示,无论有无β-巯基乙醇时,加热处理对MmPI的活性强弱无明显影响,但加热后可使MmPI的活性条带向下迁移,再次提示加热会引起其构象改变。综上述,β-巯基乙醇对MmPI的抑制活性无明显影响。
(4)葡萄糖介导的美拉德反应对MmPI活性的影响
如图9所示,100℃加热60min使MmPI的抑制活性基本丧失;有葡萄糖不加热时,MmPI对蛋白酶的抑制活性无明显影响。有葡萄糖且加热时MmPI完全失活。以上结果表明,由葡萄糖介导的美拉德反应可以降低MmPI活性。
尽管已描述了本发明的优选实施例,但本领域内的技术人员一旦得知了基本创造性概念,则可对这些实施例作出另外的变更和修改。所以,所附权利要求意欲解释为包括优选实施例以及落入本发明范围的所有变更和修改。
显然,本领域的技术人员可以对本发明进行各种改动和变型而不脱离本发明的精神和范围。这样,倘若本发明的这些修改和变型属于本发明权利要求及其等同技术的范围之内,则本发明也意图包含这些改动和变型在内。
Claims (6)
1.MmPI在制备胰蛋白酶抑制剂中的应用,其特征在于,所述MmPI具有SEQ ID NO.1所示的氨基酸序列。
2.编码权利要求1中所述MmPI的基因,其特征在于,核苷酸序列如SEQ ID NO.2所示。
3.携带权利要求2所述基因的质粒。
4.携带权利要求3所述质粒的宿主表达菌株。
5.权利要求4所述菌株的表达产物在制备胰蛋白酶抑制剂中的应用。
6.权利要求1中所述MmPI或权利要求5中所述表达产物的活性消除方法,其特征在于,包括:将MmPI置于121℃,0.21MPa环境中处理20min;或,利用由还原糖介导的美拉德反应消除。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211127625.5A CN115925847B (zh) | 2022-09-16 | 2022-09-16 | MmPI在制备胰蛋白酶抑制剂中的应用 |
PCT/CN2023/111378 WO2024008204A1 (zh) | 2022-09-16 | 2023-08-07 | MmPI在制备胰蛋白酶抑制剂中的应用 |
US18/536,572 US20240150436A1 (en) | 2022-09-16 | 2023-12-12 | Application of MmPI in Preparation of Trypsin Inhibitors |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211127625.5A CN115925847B (zh) | 2022-09-16 | 2022-09-16 | MmPI在制备胰蛋白酶抑制剂中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115925847A true CN115925847A (zh) | 2023-04-07 |
CN115925847B CN115925847B (zh) | 2023-06-20 |
Family
ID=86647878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211127625.5A Active CN115925847B (zh) | 2022-09-16 | 2022-09-16 | MmPI在制备胰蛋白酶抑制剂中的应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20240150436A1 (zh) |
CN (1) | CN115925847B (zh) |
WO (1) | WO2024008204A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024008204A1 (zh) * | 2022-09-16 | 2024-01-11 | 陕西理工大学 | MmPI在制备胰蛋白酶抑制剂中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113785933A (zh) * | 2021-09-16 | 2021-12-14 | 陕西理工大学 | 桑叶中抗营养因子类丝氨酸蛋白酶抑制剂的活性消除方法及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115925847B (zh) * | 2022-09-16 | 2023-06-20 | 陕西理工大学 | MmPI在制备胰蛋白酶抑制剂中的应用 |
-
2022
- 2022-09-16 CN CN202211127625.5A patent/CN115925847B/zh active Active
-
2023
- 2023-08-07 WO PCT/CN2023/111378 patent/WO2024008204A1/zh unknown
- 2023-12-12 US US18/536,572 patent/US20240150436A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113785933A (zh) * | 2021-09-16 | 2021-12-14 | 陕西理工大学 | 桑叶中抗营养因子类丝氨酸蛋白酶抑制剂的活性消除方法及其应用 |
Non-Patent Citations (2)
Title |
---|
HE N.J.等: "Draft genome sequence of the mulberry tree Morus notabilis", NATURE COMMUNICATIONS, pages 2445 * |
NCBI GENBANK: "NCBI Reference Sequence: XM_024167981.1, PREDICTED: Morus notabilis proteinase inhibitor (LOC21389204),mRNA", Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/nucleotide/XM_024167981.1?report=genbank&log$=nuclalign&blast_rank=1&RID=59BT9TER013> * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024008204A1 (zh) * | 2022-09-16 | 2024-01-11 | 陕西理工大学 | MmPI在制备胰蛋白酶抑制剂中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN115925847B (zh) | 2023-06-20 |
US20240150436A1 (en) | 2024-05-09 |
WO2024008204A1 (zh) | 2024-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113980112B (zh) | 一种眼镜王蛇抗菌肽oh-cath30的表达载体和表达产物及其构建制备方法 | |
CN111944837A (zh) | 一种表达covid-19抗原的表达载体及基因工程乳酸菌口服疫苗的构建方法 | |
CN115925847A (zh) | MmPI在制备胰蛋白酶抑制剂中的应用 | |
CN112851792A (zh) | 一种草鱼TNF-α重组蛋白的制备方法及其应用 | |
CN113151270A (zh) | 一种高效表达碱性蛋白酶的启动子及其应用 | |
US20240150435A1 (en) | Application of MmBBK2 in Preparation of Trypsin and Chymotrypsin Inhibitors | |
CN110616227A (zh) | 一种来源于黄粉虫的抗冻蛋白的基因、重组表达载体、工程菌株和应用 | |
CN108329384B (zh) | 一种基于噬菌体展示技术定位的加工破坏的Gly m Bd 60K蛋白抗原区域及筛选方法 | |
CN116355887A (zh) | 一种链球菌前噬菌体裂解酶lys733及其应用 | |
US20230303651A1 (en) | Method for preparing a porcine-derived interferon-delta 5 and application of porcine-derived interferon-delta 5 | |
CN112480227A (zh) | 一种提高鲟鱼抵抗病原菌能力的蛋白及其制备方法与应用 | |
CN106749615A (zh) | 一种大菱鲆生长催乳素sl基因、重组蛋白及其制备方法 | |
CN107365372B (zh) | 一种凡纳滨对虾l型凝集素及其编码基因和应用 | |
CN108977455B (zh) | 用于生产草酸脱羧酶的重组质粒、大肠杆菌表达系统及方法和应用 | |
CN114703117A (zh) | 一种重组枯草芽孢杆菌、其构建方法及一种重组胶原酶 | |
CN108840934B (zh) | 一种重组羊长效干扰素τ及制备此长效干扰素的融合蛋白及其制备方法 | |
CN110257409B (zh) | 一种红螯螯虾孵化酶基因及其应用 | |
CN111154792A (zh) | 一种隐孢子虫蛋白激酶660 c端蛋白的制备及其应用 | |
CN116640755B (zh) | 一种链球菌前噬菌体裂解酶lys1519及其应用 | |
CN109593766A (zh) | 草鱼铁调素基因及其编码的重组蛋白和应用 | |
CN116949067B (zh) | 一种神经坏死病毒cp4蛋白编码基因及制备方法与应用 | |
CN115851787B (zh) | 产亮氨酸氨肽酶的基因、枯草芽孢杆菌、构建方法和应用 | |
CN114292315B (zh) | ppc突变体及其在制备L-缬氨酸中的应用 | |
CN113528544B (zh) | 编码可溶性hpv23 l1蛋白的基因及其重组质粒的构建与应用 | |
CN114621963A (zh) | 一种猪魏氏梭菌a型的亚单位疫苗及其制备 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |